Ms. Emily Hill
Public Records Officer
4014 University Way NE
Seattle, WA 98195
Phone: 206-543-9198
Projects are approved by an IRB located at: University of Washington.
The approving IRB operates under a Multiple Project Assurance (MPA) recognized by DOE or by the Department of Health and Human Services (HHS).
MPA number of the IRB: M-1183
Number of Human Subjects Projects reported: 1
Project Identifier: UWA-92-26-009-E
Project Title:
Analytical Cytogenetics and Gene Mapping
Principal Investigator:
Dr. Barbara J. Trask
Project started in: 1992
Project Funding Information:
Project received funding in Fiscal Year 1996.
Project used human subjects in Fiscal Year 1996.
Funding Sources:
FG06-93ER61553; Amount indicated is 1/5th of total award for this project during current award period ending 9/30/96 (in no-cost extension). P.I. Barbara Trask
FG06-93ER61662; Amount indicated is 1/5th total award for project during current award period ending 9/30/96 in no-cost extension. P.I. of DOE grant: G. van den Engh and B. Trask.
subproject (PI: B. Trask) of Genome Center grant (M.V. Olson, PI).
T32 HG00035-02; Training grant. No trainees currently using human subjects, but future work has been approved under this project. Amount is 10% of total award.
Total Funding: $332,000
Project does not involve use of multiple protocols/subprojects.
IRB Review:
Type of Review: Full Board
Most Recent Approval: October 04, 1995
IRB Approval Number: 26-009-E
Number of Human Subjects who participated in this project/protocol during
FY 1996 (10/1/95 - 9/30/96): 5
Type of Human Subjects Involvement:
Note that the Project identifier is changed each year by the University of Washington IRB board. The project is now referred to as 26-009-E, but was formerly 25-023-E, 24-030-E, and 23-039-E. The project's name, Analytical Cytogenetics and Gene mapping, supplants projects of identical nature that have been conducted since 1992.
The goal of the projects covered by this human subjects project is to develop and validate improved procedures for mapping of the genome, characterization of normal variation at the DNA level, detection of chromosomal abnormalities associated with human disease, and identification of genes whose mutation causes human disease. Procedures involve flow cytometric quantification of chromosomes isolated from dividing cells, analysis of DNA sequences by polymerase chain reaction (PCR) and sequencing, and fluorescence in situ hybridization (FISH) of specific DNA sequences in dividing and non-dividing cells.
DNA sequences are mapped to their chromosomal location using peripheral blood cells from normal donors. Polymorphism in the distribution of telomeric repeats is being studied using tissue culture lines and normal control samples for FISH and DNA analyses. Chromosomal abnormalities are being detected and progress is being made toward identifying the genes involved by using FISH to map specific DNA sequences to chromosomes maintained in tissue culture lines; cells from normal donors serve as an important control for the normal pattern of hybridization.
Human subjects are involved to obtain blood for biomedical and biochemical tests outside the human body. Peripheral blood is obtained by venipuncture. Volunteers will donate 5 ml of blood, which will be collected under conventional sterile conditions. Blood samples are used to prepare microscope slide preparations or suspensions of chromosomes, either directly or after short-term culture to produce dividing cells. In some cases, DNA analyses such as PCR or hybridization are conducted. Donors fall into 2 classes: (1) normal donors (local volunteers within the department) who are more than 18 years of age, a maximum of 50 subjects per year; and (2) individuals with known chromosome abnormalities and genetic disease who are more than 18 years of age, a maximum of 50 subjects per year (although most samples in class 2 are obtained as established cell lines). Donors in the two classes will donate a maximum of 10 and 2 times per year, respectively. Normal donor samples will be identified only by a code number in subsequent experiments, thus assuring donor confidentiality. The link between code number and subject name will be kept in a locked computer file by the principal investigator (PI). Blood samples of patients will be obtained at other institutions in the course of our collaborator's experiments or during routine clinical evaluation. The samples will be encoded at the collaborating institutions, and donor identities will not be known to the investigators at the University of Washington, thus assuring donor confidentiality. The principal investigator requires that human subjects approval be obtained at the collaborating institutions for this project. Normal donors are randomly selected, balanced in numbers between males and females and different ethnic backgrounds.
The possible risks and discomforts from the procedures are considered unlikely, but include temporary pain, bruising and soreness of affected tissue or surrounding region, formation of scar tissue, and infection. No in vivo studies are performed. Samples are collected specifically for this project, but donors are selected purely on the basis of their willingness to donate blood. Some donors are asked to donate additional samples to reduce variability (normal polymorphism) in our analyses.
The study may not result in direct benefits to individual subjects, but it may contribute to the understanding and detection of human disease and may, therefore, be of some benefit to human society in the future.